Increased levels of physical activity after a diagnosis of prostate cancer are associated with significantly better survival, according to the results of a new, large prospective cohort study (Friedenreich CM, et al. Eur Urol. 2016 Jan 7. Epub ahead of print).
The regular use of aspirin reduces the incidence of and risk for death from lethal prostate cancer, according to the results of a large observational study reported at the 2016 ASCO Genitourinary Cancers Symposium. For the purposes of this study, lethal prostate cancer was defined as metastatic disease or prostate cancer–specific death.
San Antonio, TX—Supplements that are often sold in supermarkets and health food stores to promote “men’s health” or “prostate health” do not provide any clinical benefits to men with prostate cancer, according to the results of a retrospective study presented at the 2015 American Society for Radiation Oncology annual meeting. Men’s health supplements did not significantly prevent distant metastasis, prostate cancer–related death, or treatment-related adverse events in this first-of-its-kind study.
Medical and Psychosocial Impact of Oral Therapy on Patients with Metastatic Castration-Resistant Prostate Cancer
San Diego, CA—The introduction of 2 therapies for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)—the orally administered abiraterone acetate (Zytiga) and enzalutamide (Xtandi)—has prompted Leslie Hazel-Fernandez, PhD, Comprehensive Health Insights, Louisville, KY, and colleagues to conduct a qualitative study to evaluate the personal and other factors that influence the use of oral drugs among patients with mCRPC, as well as to gauge caregivers’ and physicians’ experiences with patients who use these oral medications. The results of this study were presented at the 2015 Academy of Managed Care Pharmacy annual meeting.
San Francisco, CA—In men with prostate cancer undergoing curative radiation therapy, it may be possible to preserve sexual function by using a vessel-sparing radiation technique, according to the 5-year follow-up results from a study of men who underwent vessel-sparing radiation therapy in this setting.
Anew guideline for systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC) is based on a literature review of recent publications and outlines the survival and quality-of-life benefits/toxicity effects of each recommendation.
Chicago, IL—The commercially available cell-cycle progression test known as Prolaris is helpful for stratifying risk for men with clinically localized prostate cancer and can help to modify treatment decisions for men with prostate cancer based on the aggressive nature of their tumor, according to a poster presented at the 2014 College of American Pathologists annual meeting by Michael K. Brawer, MD, Vice President of Medical Affairs, Urology, Myriad Genetic Laboratories, Inc, Salt Lake City, UT, and colleagues.
Chicago, IL—The upfront addition of docetaxel to androgen deprivation therapy (ADT) adds more than 1 year to overall survival (OS) compared with ADT alone in men with newly diagnosed hormone-sensitive prostate cancer, according to findings from a phase 3 study presented at the 2014 American Society of Clinical Oncology meeting.
Orlando, FL—Treatment with enzalutamide (Xtandi) after progression with androgen-deprivation therapy (ADT) led to a significant improvement in survival for men with metastatic castration-resistant prostate cancer (mCRPC), according to a new randomized trial reported at the 2014 American Urological Association annual meeting.
Page 1 of 4
Results 1 - 10 of 34
Results 1 - 10 of 34